Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007624 | 0.79 | CDC7 (0.33) | CDC7 | |
| SCHEMBL1006750 | 0.77 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL1007761 | 0.76 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL18632622 | 0.68 | CDC7 (0.34) | CDC7 | |
| SCHEMBL6383925 | 0.68 | ALDH1A1 (0.33) | SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL18655523 | 0.67 | CDC7 (0.33) | CDC7 | |
| SCHEMBL9938070 | 0.67 | CDC7 (0.33) | CDC7 | |
| SCHEMBL18655531 | 0.67 | ALOX5 (0.34) | CDC7 | |
| SCHEMBL18632621 | 0.67 | KDM4C (0.36) | SMN1; SMN2CDC7 | |
| SCHEMBL6381321 | 0.67 | ALDH1A1 (0.35) | SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20050107412-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| US-6831074-B2 | Inhibitors of cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDES); for use in therapy of sexual disorders | PFIZER INC | 2004-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107412-A1 | Pharmaceutically active compounds | PDE5A, PDE2A, PDE3B | SMN1; SMN2 2441/4885CYP1A2 679/4885CYP3A4 1475/4885 |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | SMN1; SMN2 3616/4885CYP1A2 2476/4885CYP3A4 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.